参考文献/References:
1 Buck AK,Schirmeister H,Mattfeldt T,et al.Biological characterization of breast cancer by means of PET.Eur J Nucl Med Mol Imaging,2004,31(Suppl 1):S80-S87.
2 Wu D,Gambhir SS.Positron emission tomography in diagnosis and management of invasive breast cancer:.Current status and future perspectives.Clin Breast Cancer,2003,4(Suppl 1):S55-S63.
3 王玲,张炽敏.乳腺肿瘤的影像学诊断进展.国外医学·放射医学核医学分册,2005,29(2):93-96.
4 Kumar A.Fluorodeoxyglucose-PET in the management of breast cancer.Radiol Clin North Am,2004,42(6):1113-1122.
5 Andrew Q,Sanjiv S G.FDG-PET and beyond:Molecular breast cancer imaging.J Clin Oncol,2005,23(8):1664-1673.
6 Wang Y,Yu J,Liu J,et al.PET-CT in the diagnosis of both primary breast cancer and axillary lymph node metastasis:initial experience.Int J Radiat Oncol Biol Phys,2003,57(Suppl 1):362-363.
7 Bellon JR,Livingston RB,Eubank WIB.Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer(LABC).Am J Clin Oncol,2004,27(4):407-410.
8 Eubank WB,Mankoff DA,Takasugi J,et al.18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer.J Clin Oncol,2001,19(12):3516-3523.
9 Lin WY,Tsai SC,Cheng KY,et al.Fluroine-18 FDG-PET in detecting local recurrence and distant metastases in breast cancer-Taiwanese experiences.Cancer Invest,2002,20(5-6):725-729.
10 Pecking Ap,Mechelany-Corone C,Bertrand-kermorgant F,et al.Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomogaphy.Clin Breast Cancer,2001,2(3):229-234.
11 Pelosi E,Messa C,Sironi S,et al.Value of integrated PET/CT for lesion localization in cancer patients:A comparative study.Eur J Nucl Med Mol Imaging,2004,31(6):932-939.
12 Uematsu T,Yuen S,Yukisawa S,et al.Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer.Am J Roentgenol,2005,184(4):1266-1273.
13 Krak NC,Hoekstra OS,Lammertsma AA.Measuring response to chemotherapy in locally advanced breast cancer:methodological considerations.Eur J Nucl Med Mol Imaging,2004,31(Suppl 1):S103-S111.
14 Schelling M,Avril N,Nahrig J,et al.Positron emission tomography using[(18)F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.J Clin Oncol,2000,18(18):1689-1695.
15 Mortimer JE,Dehdashti F,Siegel BA,et al.Metabolic flare:indicator of hormone responsiveness in advanced breast cancer.J Clin Oncol,2001,19(11):2797-2803.
16 Smyczek-Gargya B,Fersis N,Dittmann H,et al.PET with [18F]fluorothymidine for imaging of primary breast cancer:A pilot study.Eur J Nucl Med Mol Imaging,2004,31(5):720-724.
17 Pio BS,Park CK,Silverman DH.PET with fluoro-L-thymididne allows early prediction of breast cancer response to chemotherapy.J Nucl Med,2003,44(1):76-77.
18 Takamura Y,Miyoshi Y,Taguchi T,et al.Prediction of chemotherapeutic response by Technetium 99m-MIBI scintigraphy in breast carcinoma patients.Cancer,2001,92(2):232-239.
19 Fuster D,Munoz M,Pavia J,et al.Quantified 99mTc-MIBI scintigraphy for predicting chemotherapy response in breast cancer patients:factors that influence the level of 99mTc-MIBI uptake.Nucl Med Commun,2002,23(1):31-38.
20 Kim R,Osaki A,Hirai T,et al.Utility of technetium-99m methoxyisobutyl isonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancer.Breast Cancer,2002,9(3):240-247.
21 Aloj L,Zannetti A,Caraco C,et al.Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines.Eur J Nucl Med Mol Imaging,2004,31(4):521-710.
22 Del Vecchio S,Salvatore M.99mTc-MIBI in the evaluation of breast cancer biology.Eur J Nucl Med Mol Imaging,2004,31(Suppl 1):S88-S96.
23 Zhoanglin Liu,Stevenson GD,Barrett HH,et al.Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using 99mTc-labeled sestamibi and tetrofosmin.Nucl Med Biol,2005,32(6):573-583.
24 Britz-Cunning ham,SH,James-Adelstein S.Molecular targeting with radionuclides:state of the science.J Nucl Med,2003,44(12):1945-1961.
25 Bennink RJ,van Tienhoven G,Rijks LJ,et al.In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer.J Nucl Med,2004,45(1):1-7.
26 Behr TM,Behe M,Angerstein C,et al.Does pretherapeutic immunoscintigraphy allow for diagnostic predictions with respect to the toxicity and therapeutic efficacy of cold immunotherapy with trastuzumab (Herceptin)?.J Nucl Med,2000,41(1):73.
27 吴浩荣,吴锦昌.Baum R. 99mTc标记抗粘蛋白McAb乳腺癌放射免疫显像的临床研究.中华核医学杂志,2000,20(2):75-77.
28 Murakami Y,Takamatsu H,Taki J,et al.18F-labelled annexin V:a PET tracer for apoptosis imaging.Eur J Nucl Med Mol Imaging,2004,31(4):469-474.
相似文献/References:
[1]杨雷,袁卫红,王家平,等.99Tcm-MIBI显像与钼靶X线对乳腺癌诊断的比较研究[J].国际放射医学核医学杂志,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
Yang Lei,Yuan Weihong,Wang Jiaping,et al.Diagnostic value of technetium 99Tcm sestamibi and X-ray mammography in breast cancer: a comparison study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[4]孙芳芳,张欣.uPAR放射性核素靶向显像研究进展[J].国际放射医学核医学杂志,2016,40(3):230.[doi:10.3760/cma.j.issn.1673-4114.2016.03.013]
Sun Fangfang,Zhang Xin.Research progress of uPAR-targeted nuclear imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):230.[doi:10.3760/cma.j.issn.1673-4114.2016.03.013]
[5]储小飞,赵舒怡,樊赛军.肿瘤干细胞与辐射抗性的研究进展[J].国际放射医学核医学杂志,2015,39(5):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
chu xiaofei,zhao shuyi,fan saijun..advance progress of cancer stem cells and radioresistance[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
[6]安淑娴,宋少莉,黄钢.放射性核素标记的凋亡显像剂的研究进展[J].国际放射医学核医学杂志,2015,39(6):470.[doi:10.3760/cma.j.issn.1673-4114.2015.06.008]
An Shuxian,Song Shaoli,Huang Gang.Recent advances in apoptosis imaging using radionuclide-labeled tracers[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):470.[doi:10.3760/cma.j.issn.1673-4114.2015.06.008]
[7]陈伟君,孙达.99Tcm-MIBI显像在乳腺癌新辅助化疗中的应用价值[J].国际放射医学核医学杂志,2015,39(6):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
Chen Weijun,Sun Da.Clinical value of 99Tcm-MIBI imaging in neoadjuvant chemotherapy of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
[8]胡鸿,唐刚华,聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
Hu Hong,Tang Ganghua,Nie Dahong.Progress on molecular imaging of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
[9]黄建敏,解朋,刘晓梅,等.以整合素αvβ3为靶点的肿瘤分子显像及靶向治疗[J].国际放射医学核医学杂志,2015,39(3):256.[doi:10.3760/cma.j.issn.1673-4114.2015.03.015]
Huang Jianmin,Xie Peng,Liu Xiaomei,et al.Integrins αvβ3 in molecular imaging and targeted therapy of neoplasms[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):256.[doi:10.3760/cma.j.issn.1673-4114.2015.03.015]
[10]郭宵峰,刘建中,孙琦婷.肺通气/灌注平面显像与肺灌注SPECT/CT对肺栓塞诊断价值的对比性研究[J].国际放射医学核医学杂志,2015,39(4):277.[doi:10.3760/cma.j.issn.1673-4114.2015.04.001]
Guo Xiaofeng,Liu Jianzhong,Sun Qiting.Comparative study of pulmonary ventilation/perfusion planar imaging and pulmonary perfusion SPECT combined with low-dose CT in the diagnosis of pulmonary embolism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):277.[doi:10.3760/cma.j.issn.1673-4114.2015.04.001]
[11]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[12]汪秀玲,侯先存,徐凯.核医学显像在乳腺癌诊疗中的作用[J].国际放射医学核医学杂志,2006,30(4):222.
WANG Xiu-ling,HOU Xian-cun,XU Kai.The effection of nuclear medicine in the diagnosis and treat of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(4):222.
[13]郭睿,晋建华.99mTc-depreotide生长抑素受体显像的临床应用研究[J].国际放射医学核医学杂志,2007,31(3):154.
GUO Rui,JIN Jian-hua.The clinical application and study of 99mTc-depreotide somatostatin receptor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(4):154.